MindMed enters $150M ATM equity program with Leerink Partners, terminates prior ATM

Definium Therapeutics, Inc.

New at-the-market sales agreement with Leerink Partners LLC authorizes sale of up to $150M in common shares.
Agent commission capped at 3.0% of gross proceeds; company has no obligation to sell shares.
Prior Controlled Equity Offering agreement with Cantor Fitzgerald and Oppenheimer terminated on May 28, 2024.
Company may suspend or terminate the new ATM facility at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.